TORONTO, Nov. 20 /CNW/ - ARIUS Research Inc. ("ARIUS") (TSX: ARI), has
been named one of Canada's Top 10 Life Sciences Companies. Arius is dedicated
to the discovery of breakthrough cancer treatments through a unique approach
to screening for antibody drug candidates. ARIUS has attracted the attention
of large pharmaceutical companies and investors because of its focus on
antibodies with the potential to kill cancer cells while leaving normal cells
alone.
"ARIUS has gone through a transformation this year, with the completion
of a large financing, a licensing deal, a research collaboration deal, and
graduation to the Toronto Stock Exchange", said Dr. David S. Young, President
and CEO of ARIUS, "It is particularly gratifying to have our efforts
recognized by the Canadian Lifesciences Community and to be among the best
companies out there."
As one of Canada's Top 10, ARIUS will present to an audience of venture
capitalists, potential strategic alliance partners and conference delegates at
BioNorth 2006 - one of North America's premier life science conferences. ARIUS
will also participate in exclusive investment forums in New York and Boston in
January 2007 and will have the opportunity to exhibit at BIO2007.
Winning companies in Canada's Top 10 Life Sciences Competition, are
selected from a pool of entrants by an independent international jury of life
science venture capitalists. Based on their expert knowledge of investment in
the life sciences sector, the jury selects the companies that offer the best
investment and partnership prospects.
About ARIUS
ARIUS Research Inc. is a biotechnology company dedicated to personalizing
cancer therapy through the discovery and development of novel anticancer
monoclonal antibodies (MAbs). Established in 1999, ARIUS has built a
proprietary technology platform, FunctionFIRST(TM), that rapidly identifies
powerful MAbs targeting a variety of cancer indications. This antibody
generation engine has enabled ARIUS to assemble a growing pipeline, which is
used for commercial collaborations and in-house development. ARIUS has ongoing
partnerships with key biotechnology and drug development companies. The
company is listed on the TSX under the symbol "ARI".
Forward-Looking Statement
Certain statements in this news release constitute "forward-looking
statements" within the meaning of the Private Securities Litigation Reform Act
of 1995, which involve known and unknown risks, uncertainties and other
factors that may cause our actual results to be materially different from any
future results, performance or achievements expressed or implied by such
statements. Forward-looking statements in this release include, but are not
limited to, ARIUS successfully advancing its new product programs as well as
licensing opportunities. These statements are only predictions and actual
events or results may differ materially. Factors that could cause such actual
events or results expressed or implied by such forward-looking statements to
differ materially from any future results expressed or implied by such
statements include, but are not limited to: early stage of development;
technology and product development; dependence on and management of current
and future corporate collaborations; future capital needs; uncertainty of
additional funding; no assurance of market acceptance; dependence on
proprietary technology and uncertainty of patent protection; intense
competition; manufacturing and market uncertainties; and government
regulation. These and other factors are described in detail in ARIUS' Annual
Report, forthcoming news releases and other filings with Canadian securities
regulatory authorities available at www.sedar.com. Forward-looking statements
are based on our current expectations and ARIUS is not obligated to update
such information to reflect later events or developments.
%SEDAR: 00013708E
